SVB Securities Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)

SVB Securities analyst Marc Goodman maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLXResearch Report) on August 11 and set a price target of $31.00. The company’s shares closed yesterday at $25.27.

According to TipRanks, Goodman is a 3-star analyst with an average return of 2.5% and a 48.45% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Jazz Pharmaceuticals, and Neurocrine.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $30.25 average price target, which is a 19.71% upside from current levels. In a report released on August 12, Citigroup also maintained a Buy rating on the stock with a $35.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $33.41 and a one-year low of $6.51. Currently, Amylyx Pharmaceuticals Inc has an average volume of 969.4K.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMLX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Read More on AMLX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More